molecules molecules molecules molecules molecules molecules

ANTI-PD-1 – ZIMBERELIMAB

Our Science > Clinical Candidates > Zimberelimab
ABOUT ZIMBERELIMAB

Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity.

Arcus is evaluating zimberelimab in combination with casdatifan in clear cell renal cell carcinoma.

Zimberelimab is currently approved in China for the treatment of classical Hodgkin lymphoma and recurrent/metastatic cervical cancer. Gloria Biosciences secured the Chinese approval and holds commercial rights in China. It conducts its development activities independently of Arcus.

See all zimberelimab clinical trials
See all zimberelimab presentations

The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established.

Next:
 Casdatifan
>>>

Explore More

documents icon

Read our latest press releases and announcements

Browse
handshake icon

Join forces with us on our mission to defeat cancer

Connect
clinical trial icon

Arcus clinical trials are currently enrolling

Sign Up
Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.

© 2026 Arcus Biosciences, Inc.  All rights reserved.

3928 Point Eden Way, Hayward, CA 94545